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venous and arterial thrombosis, recurrent fetal 
losses, and serologically by the presence of an-
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Abstract
Background. Thrombotic events in antiphospholipid syndrome (APS) involve venous and arterial circulation with 
the possible involvement of coronary or pulmonary microcirculation.
Objectives. To evaluate the influence of antiphospholipid antibodies (aPL) and on myocardial ischaemia assessed 
by single-photon emission computerized tomography (SPECT), coronary atherosclerosis assessed by multidetector 
computerized tomography (MDCT) and pulmonary pressure assessed by transthoracic echocardiography (TTE) in 
patients with primary antiphospholipid syndrome (PAPS).
Material and Methods. TTE, SPECT (Tc 99m sestamibi) and MDCT-based coronary calcium scoring were per-
formed in 26 consecutive PAPS patients (20 females, 6 males, aged 20−61, mean 39.7) without any signs of other 
autoimmunological disease and without clinical symptoms of heart disease.
Results. Out of 26  patients, TEE showed normal left and right ventricle function in 25 (96.2%) and elevated 
(≥ 30 mm Hg) right ventricle systolic pressure in 7 (26.9%) patients. SPECT revealed myocardial perfusion defects 
in 15 (57.7%) patients: exercise-induced in 6 (23.1%) and persistent in 11 (42.3%). MDCT revealed coronary cal-
cifications in 4 (15.4%) patients. The number of plaques ranged from 1 to 11 (median 2), volume 3−201.7 mm³ 
(median 7), calcium scores 1.3–202.6 (median 5.7). In the group with perfusion defects or coronary calcifications 
(n = 15), all the patients showed elevated aCL IgG.
Conclusions. In  most of the relatively young APS patients, without any symptoms of ischemic heart disease, 
SPECT showed myocardial perfusion defects, and coronary calcifications in 1/6 of them. Right ventricle systolic 
pressure was elevated in 1/4 of APS patients. These pathologies, well known as cardiovascular risk markers, were 
associated with elevated levels of the IgG class of both anti-cardiolipin and antiB2 GPI antibodies. Thus, in a high 
percentage of APS patients, clinically silent myocardial ischaemia, pulmonary pressure elevation and coronary 
atherosclerosis are present and related to the presence of antiphospholipid antibodies (Adv Clin Exp Med 2016, 
25, 6, 1199–1205).
Key words: antiphospholipid syndrome, anti-cardiolipin antibodies, anti-beta 2 glycoprotein I antibodies, pulmo-
nary arterial pressure, myocardial ischaemia.
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cardiolipin (aCL) and antiβ2-glycoprotein I  GPI 
(antiβ2-GPI) antibodies as well as positive lupus 
anticoagulant [1].
Thrombotic events in APS involve venous 
and arterial circulation with the possible involve-
ment of coronary or pulmonary microcirculation. 
This may influence myocardial function and pul-
monary vascular resistance and pressure. The pro-
thrombotic action of aPL may share a few common 
pathways with atherosclerosis  [2]. Early clinical 
observations have suggested that aPL may contrib-
ute to the development of atherosclerosis in sys-
temic lupus erythematosus and also in primary 
APS (PAPS). Increased levels of aPL have also been 
detected in young/middle-aged patients who suf-
fer from accelerated atherosclerotic disease [3−5]. 
However, little is known about the objective signs 
of atherosclerosis development in APS. Asymp-
tomatic atherosclerosis as assessed by ultrasonog-
raphy occurs in 15% of APS patients compared to 
3% in normal controls [6]. In the Euro-Phospho-
lipid cohort of 1000 APS patients, myocardial in-
farction appeared in 5.5% during the course of the 
disease [7].
However, considering the low sensitivity of 
clinical symptoms and electrocardiography (ECG) 
for the diagnosis of past acute coronary syn-
dromes, the real prevalence of MI in APS might 
probably be higher. For example, using more ad-
vanced methodology (cardiac magnetic resonance 
imaging), silent myocardial ischaemia was found 
in 29.6% of APS patients [8].
The  present study was conducted to evaluate 
cardiac involvement in PAPS and the possible in-
fluence of antiphospholipid antibodies and lupus 
anticoagulant on heart pathologies.
Material and Methods
The  study was performed in 26 consecutive 
patients treated for PAPS in the Department of In-
ternal Medicine, Jagiellonian University Medical 
College, Krakow.
All patients met the Sydney Classification cri-
teria for APS [1]. Exclusion criteria included: preg-
nancy or lactation at the time of the study and 
known hypersensitivity to any of the substanc-
es used during the study. All patients were in sta-
ble clinical condition and at least 12  months af-
ter the last venous/arterial thrombosis or fetal loss 
 episode.
In  all the patients, SPECT studies (ECAM 
Gamma Camera, Siemens, Germany) at rest 
and during exercise (2-day protocol) were per-
formed. On the first day, at near maximal stress, 
a 25−40 mCi dose of Tc-99m sestamibi was inject-
ed (actual patient dose was modified taking into 
account the patient’s weight) and exercise contin-
ued for 1 additional minute after injection. Tc-99m 
sestamibi SPECT imaging was begun 15−30  min 
later. On the second day, rest examinations were 
performed. SPECT was performed using a  circu-
lar 180° acquisition for 60 projections at 20 s per 
projection. Myocardial perfusion was assessed in 
17 left ventricle myocardial segments. The number 
of segments with rest (persistent) or exercise-in-
duced perfusion defects were assessed by visual in-
terpretation by analyzers blinded for all other in-
formation.
Coronary calcium scoring was performed us-
ing a multidetector CT imager (Somatom Defini-
tion, Siemens, Germany). The  images were ECG 
triggered. The  3-millimeter-thick sections were 
obtained covering the whole heart. Coronary ar-
tery calcifications were defined as lesions with at-
tenuation greater than 130 HU in more than four 
adjacent pixels. For quantification of the coronary 
calcium, the 3D Leonardo application (Siemens, 
Germany) was used. The  number of atheroscle-
rotic plaques in particular coronary arteries and its 
volume were assessed. The Agatson calcium score 
was calculated [9].
Standard laboratory tests were performed, in-
cluded fasting glucose and cholesterol level, cre-
atinine concentration, transaminase activity and 
CRP level. aCL and aβ2GPI were determined in 
the patients sera using QUANTA  Lite® aCL and 
β2GPI (IgG and IgM) tests [Inova Diagnostics, San 
 Diego, USA. The QUANTA Lite aCL assays report 
results in GPL and MPL units, and the QUANTA 
Lite β2GPI assays report results in standard IgG 
and IgM units (SGU and SMU, respectively)]. All 
QUANTA Lite ELISAs were performed according 
to the manufacturer’s guidelines.
Lupus anticoagulant (LA) was determined in 
a three-step procedure according to the guidelines 
of the ISTH. Diluted Russell’s viper venom time 
(dRVVT; LA1-screen; Siemens, Germany) and 
a  sensitive activated partial thromboplastin time 
(PTT LA; Diagnostica Stago, France) were used 
for screening purposes, whereas LA2-confirm (Sie-
mens, Germany) and Staclot LA (Diagnostica Sta-
go, France) were run as confirmatory tests. Refer-
ence values for each test were established using the 
99th percentile of the healthy population [10].
Statistical analysis was performed using STA-
TISTICA Six Sigma software. All numerical data 
was expressed as mean values standard deviation, 
medians or as proportions. Continuous vari-
ables were compared by use of a t-test. The c2 test 
was used to examine differences in proportions. 
The  level for statistical significance was predeter-
mined at p < 0.05.
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Before the study, informed consent was ob-
tained from each patient. The study protocol con-
forms to the ethical guidelines of the 1975 Dec-
laration of Helsinki. The  study was approved by 
Ethical Committee of the Jagiellonian University 
in Krakow.
Results
In the group of 26 patients examined, 20 were 
female, 6 male, aged 20−61 (mean age 39.7 years). 
One patient had a  history of an objectively con-
firmed pulmonary embolism. None of the patients 
had a  prior history of coronary artery disease. 
None of the patients had the classic risk factors for 
coronary artery disease. ECG recordings were nor-
mal in all the patients. Laboratory results showed 
that out of 26 patients studied, 4 were single-pos-
itive (one type of the antiphospholipid antibody 
present), 5 double-positive, and 17 triple-positive.
Echocardiography showed normal left and 
right ventricle function in 25 (96.2%) patients (left 
ventricle ejection fraction 45−75%, mean 63.95%). 
In 2 (7.7%) patients, mild mitral insufficiency was 
diagnosed. In 7 (26.9%), tricuspid insufficiency was 
present with the elevation of right ventricle systol-
ic pressure  ≥  30  mm  Hg (RVSP 31−40  mm  Hg, 
mean 36.1 ±  3.2  mm  Hg). SPECT revealed myo-
cardial perfusion defects in 15 (57.7%) patients: 
exercise-induced in 6 (23.1%), persistent in 11 
(42.3%). MDCT revealed coronary calcifications in 
4 (15.4%) patients. The number of plaques ranged 
from 1 to 11 (median 2), volume 3−201.7  mm³ 
(median 7 mm³), calcium scores 1.3−202.6 (medi-
an 5.7).
In patients with elevated right ventricular sys-
tolic pressure (n = 7) all had elevated IgG class aCL 
and the majority showed the presence of LA and 
elevated IgG anti-β2-GPI (Table 1).
The  percentage of out-of-range immunolog-
ical results in patients without RVSP elevation 
was lower as compared to the patients with RVSP 
≥ 30 mm Hg, however the difference was not sta-
tistically significant (Table 1).
In  the group with perfusion defects or coro-
nary calcifications (n = 15), all the patients had el-
evated IgG class aCL and, 66.7% had elevated IgG 
class antiβ2-GPI, and LA was present in 86.7% of 
them (Table  2). The  percentage of out-of-range 
immunological results in patients without myocar-
dial perfusion defects and with no coronary cal-
cifications was lower, however the difference was 
again not statistically significant (Table 2).
SPECT or MDCT showed pathologies in 1 (25%) 
single-positive patient, 3 (60%) double-positive 
patients and 11 (64.7%) triple-positive patients. 
There were no single-positive patients with RVSP 
elevation (Table 3).
Fig. 1 shows the examples of coronary calcifi-
cations and myocardial perfusion defects observed 
in a patient with elevated aPL levels.
Discussion
The major finding of this study was the high 
frequency of left ventricle myocardial perfusion 
defects and the elevation of right ventricle systol-
ic pressure in a high percentage of APS patients.
The previous data showing myocardial perfu-
sion defects in autoimmune diseases referred mainly 







mean ± SD number (%) of patients 
with levels out of range
mean ± SD number (%) of patients 
with levels out of range
aCL IgG
[RU/mL]
51.4 ± 40.9 17 (89.5%) 70.0 ± 48.8 7 (100.0%)
aCL IgM
[RU/mL]
40.5 ± 59.6 8 (42.1%) 26.3 ± 15.5 5 (71.4%)
antiβ2GPI IgG
[RU/mL]
42.8 ± 54.9 11 (57.9%) 60.3 ± 46.6 5 (71.4%)
antiβ2GPI IgM
[RU/mL]
55.6 ± 102.8 7 (36.8%) 13.0 ± 16.3 1 (14.3%)
LA − 15 (88.2%) − 6 (85.7%)
aCL – anticardiolipin antibodies (cut-off value for IgG > 20 RU/mL, for IgM > 30 RU/mL; see methods); antiβ2GPI – antiβ2- 
-glycoprotein I antibodies (cut-off value for IgG > 3 RU/mL, for IgM > 2.6 RU/mL; see methods); LA – lupus anticoagulant.
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Table 3. Number of patients with elevated right ventricular systolic pressure (RVSP), myocardial perfusion defects (SPECT +) 
or coronary calcium deposits (CT +) according to laboratory findings
Positivity Number (%) of patients 
with RVSP > 30 mm Hg
Number (%) of patients 
with SPECT (+)
Number (%) of patients 
with CT (+)
single (n = 4) 0 (0.0%) 1 (25.0%) 1 (25.0%)
double (n = 5) 3 (60.0%) 3 (60.0%) 1 (20.0%)
triple (n = 17) 4 (23.5%) 11 (64.7%) 2 (11.8%)




SPECT (−) and CT (−)
n = 11
SPECT (+) or CT (+)
n = 15
mean ± SD number (%) of patients 
with levels out of range
mean ± SD number (%) of patients 
with levels out of range
aCL IgG
[RU/mL]
44.6 ± 40.7 9 (81.8%) 65.1 ± 43.8 15 (100.0%)
aCL IgM
[RU/mL]
42.8 ± 68.7 5 (45.5%) 32.2 ± 36.3 8 (53.3%)
antiβ2GPI IgG
[RU/mL]
41.3 ± 57.6 6 (54.5%) 52.1 ± 49.9 10 (66.7%)
antiβ2GPI IgM
[RU/mL]
68.4 ± 126.6 4 (36.4%) 26.3 ± 49.9 4 (26.7%)
LA − 8 (72.7%) − 13 (86.7%)
aCL – anticardiolipin antibodies (cut-off value for IgG > 20 RU/mL, for IgM > 30 RU/mL; see methods); antiβ2GPI – antiβ2- 
-glycoprotein I antibodies (cut-off value for IgG > 3 RU/mL, for IgM > 2.6 RU/mL; see methods); LA – lupus anticoagulant.
Fig. 1. Examples of MDCT (above) and 
SPECT (below) results in a patient with 
elevated aCL IgG (26.11 RU/mL), ele-
vated antiβ2GPI IgG (3.66 RU/mL) and 
positive lupus anticoagulant test
In MDCT study, 2 calcified plaques 
are present in le anterior 
descending artery (red color)  
and 1 calcified plaque in circumflex 
artery  (blue color). Plaque volume 
156.4  mm  , calcium score 138.9.3
aorta
In SPECT study, perfusion defect  
is present in anterior wall of le 
ventricle (arrow).
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to systemic lupus erythematosus (SLE)  [11−13] or 
rheumatoid arthritis (RA) [14]. There is  only a sin-
gle study referring to PAPS. In SLE, perfusion de-
fects were detected in 36−38% of asymptomatic 
patients [14, 15], and when assessed globally in au-
toimmune diseases (such as SLE, RA and PAPS) it 
was slightly lower, 27%  [13], despite normal rest 
ECG recordings and lack of myocardial ischaemia 
clinical symptoms. To  the best of our knowledge, 
this is the first study which shows such a high fre-
quency of myocardial perfusion defects in relatively 
young PAPS patients who were free from classic 
risk factors and symptoms of ischemic heart dis-
ease. We found perfusion disturbances in 57.7% of 
the patients examined. The abnormalities were pre-
dominantly observed at rest, indicating persistent 
myocardial injury. It has to be stressed that perfu-
sion defects revealed by SPECT strongly affect the 
prognosis in non-autoimmune populations [16, 17].
We found only two studies that assessed myo-
cardial perfusion in PAPS patients. In  the first, 
involving 18  patients with PAPS and using (13)
N-ammonia positron emission tomography, the 
authors showed the presence of myocardial isch-
aemia in 38.8% (7/18) of their patients  [18]. This 
study referred to older patients and a greater pro-
portion of males as compared to our patients. 
The  second study, of 11 PAPS patients, revealed 
heart perfusion defects in 30% of them by using 
contrast echocardiography and sestamibi spec-
trometry. None of these studies analyzed right 
ventricle systolic pressure.
Right ventricle systolic pressure elevation may 
form a second factor influencing the prognosis in 
APS patients. Data from the literature suggests 
that in autoimmune diseases even slight changes 
in pulmonary circulation lead to a  significant de-
crease in physical activity capacity [19]. Thus, even 
slightly elevated (30−40  mm  Hg) right ventricle 
systolic pressure, observed in 1/3 of our patients, 
may be prognostically important. This is the first 
report showing a high frequency of RVSP elevation 
in a stable, otherwise unselected group of APS pa-
tients. In the patients with RVSP elevation, all were 
IgG class aCL-positive and 71.4% had elevated IgG 
class antiβ2-GPI (the frequency of IgG class antiβ2-
GPI-positivity in the normal RVSP group was 
57.9%). Recently, Cefle et al. [20] showed a higher 
frequency of aCL positivity in 10 SLE patients with 
pulmonary hypertension as compared to 97 SLE 
patients with normal pulmonary pressure, but in 
that study, echocardiography was performed only 
in patients with clinical or radiological symptoms 
suggesting pulmonary involvement. However, the 
precise levels of aCL were not reported.
In another study, of 39 mixed connective tis-
sue disease patients, the presence of pulmonary 
hypertension was associated with higher levels of 
antiβ2GPI antibodies  [21]. Interestingly, SPECT 
examination also revealed an association between 
elevated levels of aCL IgG and antiβ2GPI IgG an-
tibodies and myocardial perfusion abnormalities. 
It  is tempting to speculate that the perfusion de-
fects might have been a result of endotheliopathy 
with microangiopathy caused by small, otherwise 
undetected thrombi formed in the coronary mi-
crocirculation, which in turn have led to the per-
fusion defects at rest in several small regions of the 
left ventricle myocardium. Of note, we never ob-
served a pattern characteristic of classic coronary 
artery disease due to closed large epicardial artery, 
which typically manifests by larger, sharp-edged 
defects in the region supplied by a particular cor-
onary artery. Quite a  similar mechanism may be 
involved in aPL-associated pulmonary pressure 
elevation; namely microembolism/thrombosis of 
pulmonary microcirculation resulting in increased 
pulmonary resistance with RV systolic pressure el-
evation. A parallel mechanism may also involve in-
timal proliferation similar to that described in kid-
ney microcirculation [22]
Besides the presence of myocardial perfusion 
abnormalities and right ventricle pulmonary pres-
sure elevation, 15.4% of our asymptomatic APS 
patients manifested atherosclerosis in coronary 
arteries. Coronary vessels are most frequently af-
fected by calcifications in autoimmune diseases. 
In a study of 50 SLE patients [23], high frequency 
of atherosclerotic plaques as shown by MDCT was 
observed in coronary arteries (42% of patients with 
calcifications), followed by carotid arteries (24% of 
patients with calcifications). The frequency of coro- 
nary calcifications in our APS group was lower 
than that reported in SLE. Still, coronary calcium 
deposits provide independent prediction of short- 
and long-term cardiac events [24, 25]. Even in pa-
tients with normal SPECT results, an increased 
coronary calcium score identifies subjects at high 
long-term cardiac risk [24]. Antiphospholipid an-
tibodies may initiate or exacerbate the process of 
lipid deposition and plaque formation. Among 
antiphospholipid antibodies, a  crucial role in the 
pathogenesis of atherosclerosis is attributed to aCL 
antibodies and antiβ2GPI antibodies [26, 27].
Our results may also have implications for the 
management of APS patients. The presence of ath-
erosclerotic plaques and myocardial perfusion de-
fects in a  SPECT study are strong predictors of 
death [16, 17, 24, 25]. The mechanism of these ab-
normalities, in which microthrombosis might play 
a major role, should direct our attention to throm-
bosis prevention. Generally, in APS patients with-
out clinically observable venous or arterial throm-
bosis, anticoagulation is not recommended, despite 
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the aPL titers. However, it was reported that in as-
ymptomatic aCL-positive patients, thrombo-pro-
phylaxis with aspirin or low-molecular weight 
heparin during high-risk periods (surgery, im-
mobilization) is effective at reducing thrombot-
ic complications [28]. Among asymptomatic aCL-
positive SLE patients, primary prophylaxis with 
aspirin and hydroxychloroquine also reduced the 
frequency of thrombotic events [29]. The value of 
antithrombotic treatment on perfusion abnormali-
ties, pulmonary arterial pressure and coronary cal-
cification formation, and as a consequence on the 
prognosis of APS patients, should be addressed in 
large prospective clinical trials.
In  conclusion, in most relatively young APS 
patients, SPECT shows myocardial perfusion de-
fects with coronary calcifications present in 1/6 of 
them. Right ventricle systolic pressure is elevat-
ed in 1/4 of APS patients. These pathologies, well-
known as cardiovascular risk markers, are com-
bined with elevated levels of anticardiolipin and 
antiβ2-GPI antibodies of the IgG class. Thus, in 
a high percentage of APS patients, clinically silent 
myocardial ischaemia, pulmonary pressure eleva-
tion and coronary atherosclerosis are present, and 
causally related to the presence of antiphospholip-
id antibodies. The  value of antithrombotic treat-
ment on perfusion abnormalities, pulmonary arte-
rial pressure and coronary calcification formation, 
and as a consequence on the prognosis of APS pa-
tients, should be addressed in large prospective 
clinical trials.
References
 [1] Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG, Koike T, 
Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA: International consensus state-
ment on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Heamost 
2006, 4, 295−306.
 [2] Ross R: Atherosclerosis − an inflammatory disease. N Engl J Med 1999, 340, 115−126.
 [3] Sherer Y, Shoenfeld Y: Antiphospholipid antibodies: Are they proatherogenic or an epiphenomenona of athero-
sclerosis? Immunobiology 2003, 207, 13–16.
 [4] Nityanand S, Bergmark C, de Faire U, Swedenborg J, Holm G, Lefvert AK: Antibodies against endothelial cells 
and cardiolipin in young patients with peripheral atherosclerotic disease. J Intern Med 1995, 238, 437–443.
 [5] Vaarala O, Mänttäri M, Manninen V, Tenkanen L, Puurunen M, Aho K, Palosuo T: Anti-cardiolipin antibodies 
and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 1995, 91, 23−27.
 [6] Comarmond C, Cacoub P: Antiphospholipid syndrome: From pathogenesis to novel immunomodulatory thera-
pies. Autoimmun Rev 2013, 12, 752−757.
 [7] Cervera  R, Piette  JC, Font  J, Khamashta  MA, Shoenfeld  Y, Camps  MT, Jacobsen  S, Lakos  G, Tincani  A, 
Kontopoulou-Griva  I, Galeazzi  M, Meroni  PL, Derksen  RH, de Groot  PG, Gromnica-Ihle  E, Baleva  M, 
Mosca  M, Bombardieri  S, Houssiau  F, Gris  JC, Quéré  I, Hachulla  E, Vasconcelos  C, Roch  B, Fernández-
Nebro A, Boffa MC, Hughes GR, Ingelmo M; Euro-Phospholipid Project Group Antiphospholipid syndrome: 
Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis 
Rheum 2002, 46, 1019−1027.
 [8] Sacré K, Brihaye B, Hyafil F, Serfaty JM, Escoubet B, Zennaro MC, Lidove O, Laissy JP, Papo T: Asymptomatic 
myocardial ischemic disease in antiphospholipid syndrome: A  controlled cardiac magnetic resonance imaging 
study. Arthritis Rheum 2010, 62, 2093−2100.
 [9] Agatson  AS, Janowitz  WR, Hildner  FJ, Zusmer  NR, Viamonte  M  Jr, Detrano  R: Quantification of coronary 
artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990, 15, 827−832.
[10] Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, De Groot PG: Update of the guidelines for lupus 
anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and 
Standarisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009, 
7, 1737−1740.
[11] Plazak  W, Pasowicz  M, Kostkiewicz  M, Podolec  J, Tomkiewicz-Pajak  L, Musial  J, Podolec  P: Influence of 
chronic inflammation and autoimmunity on coronary calcifications and myocardial perfusion defects in systemic 
lupus erythematosus patients. Inflamm Res 2011, 60, 973−980.
[12] Lin  CC, Ding  HJ, Chen  YW, Wang  JH, Ho  ST, Kao  A: Usefulness of technetium-99m sestamibi myocardial 
perfusion SPECT in detection of cardiovascular involvement in patients with systemic lupus erythematosus or 
systemic sclerosis. Int J Cardiol 2003, 92, 157−161.
[13] Espinola-Zavaleta  N, Alexanderson  E, Granados  N, Soto  ME, Amigo  MC: Myocardial perfusion defects in 
patients with autoimmune diseases: A prospective study. Analysis of two diagnostic tests. Lupus 2006, 15, 38–43.
[14] Baharfard  N, Shiroodi  MK, Fotoohi  F, Samangooie  S, Asli  IN, Eghtesadi-Araghi  P, Javadi  H, Semnani  S, 
Amini A, Assadi M: Myocardial perfusion imaging using a technetium-99m sestamibi in asymptomatic and low 
risk for coronary artery disease patients with diagnosed systemic lupus erythematosus. Perfusion 2011, 26, 151−157.
[15] Sun SS, Shiau YC, Tsai SC, Lin CC, Kao A, Lee CC: The  role of technetium-99m sestamibi myocardial per-
fusion single-photon emission computed tomography (SPECT) in the detection of cardiovascular involvement 
in systemic lupus erythematosus patients with non-specific chest complaints. Rheumatology (Oxford) 2001, 40, 
1106−1111.
Heart Ischaemia in Antiphospholipid Syndrome 1205
[16] Vanzetto G, Ormezzano O, Fagret D, Comet M, Denis B, Machecourt J: Long term additive prognostic value of 
thalium-201 myocardial perfusion imaging over clinical and exercise stress test in low to intermediate risk patients: 
Study in 1137 patients with 6-year follow-up. Circulation 1999, 100, 1521−1527.
[17] Hachamovitch R, Berman DS, Shaw LJ, Kiat H, Cohen I, Cabico JA, Friedman J, Diamond GA: Incremental 
prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of car-
diac death: Differential stratification for risk of cardiac death and myocardial infarction. Circulation 1998, 17, 97, 
535−543.
[18] Alexánderson  E, Gómez-León  A, Vargas  A, Romero  JL, Sierra  Fernández C, Rodriguez  Valero M, García-
Rojas L, Meave A, Amigo MC: Myocardial ischaemia in patients with primary APS: A 13N-ammonia PET assess-
ment. Rheumatology (Oxford) 2008, 47, 894−896.
[19] Kovacs G, Maier R, Aberer E: Borderline pulmonary arterial pressure is associated with decreased exercise capac-
ity in scleroderma. Am J Respir Crit Care Med 2009, 180, 881−886.
[20] Cefle A, Inanc M, Sayarlioglu M, Kamali S, Gul A, Ocal L, Aral O, Konice M: Pulmonary hypertension in sys-
temic lupus erythematosus: Relationship with antiphospholipid antibodies and severe disease outcome. Rheumatol 
Int 2011, 31, 183−189.
[21] Hasegawa EM, Caleiro MT, Fuller R, Carvalho JF: The frequency of anti-beta2-glycoprotein I antibodies is low 
and these antibodies are associated with pulmonary hypertension in mixed connective tissue disease. Lupus 2009, 
18, 618−621.
[22] Canaud  G, Bienaimé  F, Tabarin  F, Bataillon  G, Seilhean  D, Noël  LH, Dragon-Durey  MA, Snanoudj  R, 
Friedlander G, Halbwachs-Mecarelli L, Legendre C, Terzi F: Inhibition of the mTORC pathway in the antiphos-
pholipid syndrome. N Engl J Med. 2014, 371, 303−312.
[23] Yiu KH, Wang S, Mok MY, Ooi GC, Khong PL, Mak KF, Lam KF, Lau CS, Tse HF: Pattern of arterial calcifica-
tion in patients with systemic lupus erythematosus. J Rheumatol 2009, 36, 2212−2217.
[24] Polonsky TS, McClelland RL, Jorgensen NW, Bild DE, Burke GL, Guerci AD, Greenland P: Coronary artery 
calcium score and risk classification for coronary heart disease prediction. JAMA 2010, 303, 1610−1616.
[25] Uebleis C, Becker A, Griesshammer I, Cumming P, Becker C, Schmidt M, Bartenstein P, Hacker M: Stable 
coronary artery disease: Prognostic value of myocardial perfusion SPECT in relation to coronary calcium scoring 
– long-term follow-up. Radiology 2009, 252, 682−690.
[26] Glueck CJ, Lang JE, Tracy T, Sieve-Smith L, Wang P: Evidence that anticardiolipin antibodies are independent 
risk factors for atherosclerotic vascular disease. Am J Cardiol 1999, 83, 1490−1494.
[27] Le Tonquèze M, Salozhin K, Dueymes M, Piette JC, Kovalev V, Shoenfeld Y, Nassonov E, Youinou PY: Role of 
β2-glycoprotein I in the antiphospholipid antibody binding to endothelial cells. Lupus 1995, 4, 179−186.
[28] Giron-Gonzales  JA, Garcia del Rio  E, Rodriguez  C, Rodriguez-Martorell  J, Serrano  A: Antiphospholipid 
syndrome and asymptomatic carriers of antiphospholipid antibody: Prospective analysis of 404 individuals. 
J Rheumatol 2004, 31, 1560−1567.
[29] Wahl DG, Bounameaux H, de Moerloose P, Sarasin FP: Prophylactic antithrombotic therapy for patients with 
systemic lupus erythematosus with or without antiphospholipid antibodies: Do the benefits outweigh the risks? 
A decision analysis. Arch Intern Med 2000, 160, 2042−2048.
Address for correspondence:
Agnieszka Padjas
Department of Internal Medicine, Allergy and Immunology




Tel.: +48 124 30 52 66
E-mail: agnieszkapadjas@gmail.com
Conflict of interest: None declared
Received: 4.03.2016
Revised: 7.05.2016
Accepted: 17.06.2016
